COVID-19 (SARS-CoV-2 - Coronaviruses)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
COVID-19 is caused by SARS-CoV-2. It spreads mainly through infectious respiratory particles in the air, including during ordinary breathing and talking; people can spread it before symptoms or without symptoms. Illness ranges from no symptoms or a cold-like infection to pneumonia and severe disease. Older age, immune suppression and certain medical conditions increase risk. Vaccination reduces severe outcomes, and eligible higher-risk patients may benefit from early antiviral treatment. Some people develop persistent symptoms called Long COVID, even after an initially mild illness.
Clinical Definition
COVID-19 is infection-related illness caused by SARS-CoV-2, an enveloped, nonsegmented, positive-sense single-stranded RNA betacoronavirus. Spike binds ACE2, with host protease processing enabling entry. Infection commonly involves the upper airway and may extend to the lungs. Severe disease can involve diffuse alveolar damage, hypoxemia, inflammatory dysregulation and thrombosis. The spectrum includes asymptomatic infection, mild respiratory illness, severe pneumonia and critical multiorgan disease. Symptoms, incubation and treatment effectiveness vary with host immunity and viral variants; detection of viral RNA alone does not establish current infectiousness.
Inciting Event
Inhalation or direct mucosal deposition of infectious respiratory particles from an infected person is the main transmission route.
Close contact with symptomatic or asymptomatic carriers in enclosed spaces.
Airborne exposure can occur during breathing, talking, singing or coughing, especially in poorly ventilated indoor spaces; aerosol-generating procedures add risk.
Transmission from contaminated surfaces is possible but less important than respiratory spread.
Latency Period
Incubation varies by variant and host; Omicron-era estimates often center around 3–4 days, shorter than early-pandemic estimates.
Symptoms may occur within a few days, with a wider possible range; one fixed median should not be applied to every variant.
Asymptomatic infection can occur despite viral replication during this period.
Diagnostic Delay
Initial symptoms often mimic common viral illnesses leading to misattribution as influenza or common cold.
Testing too early, poor sampling or lower antigen sensitivity can delay detection; do not let testing delays consume the early antiviral treatment window in eligible patients.
Asymptomatic or mild cases may not seek medical attention, delaying detection.
Overlap with other respiratory infections complicates clinical diagnosis without testing.
Clinical Presentation
Signs & Symptoms
Symptoms may include sore throat, congestion, cough, fever and fatigue; presentation varies and fever may be absent.
Dyspnea develops in moderate to severe cases indicating lower respiratory tract involvement.
Loss of smell or taste can occur, but is less frequent with some later variants and is neither required nor specific enough to replace testing.
Myalgias and headache frequently accompany systemic viral illness.
Gastrointestinal symptoms such as diarrhea and nausea occur in a subset of patients.
History of Present Illness
Initial symptoms commonly include fever, dry cough, and fatigue progressing over days.
Dyspnea or hypoxemia can signal progression, but timing varies; do not wait for a fixed day of illness to assess deterioration.
Some patients report anosmia and ageusia as early or isolated symptoms.
Gastrointestinal symptoms like diarrhea and nausea may precede respiratory complaints.
Severe cases progress to ARDS, multi-organ failure, and shock.
Past Medical History
Chronic lung diseases such as COPD or asthma increase risk of severe COVID-19.
Cardiovascular diseases including hypertension and heart failure worsen prognosis.
Diabetes mellitus is associated with impaired immune response and complications.
History of immunosuppressive therapy or conditions increases susceptibility.
Previous vaccination status against COVID-19 modifies disease severity and outcomes.
Family History
Most household clustering reflects exposure, but rare inborn errors of antiviral immunity can predispose to severe COVID-19.
Family clusters are common due to shared exposure and transmission rather than genetics.
Rare genetic variants affecting type I interferon pathways may predispose to severe disease.
Rare inherited immune defects are distinct from typical household spread; family history alone does not reliably predict severity.
Physical Exam Findings
Fever and tachypnea are common vital sign abnormalities in COVID-19 patients.
Hypoxia with decreased oxygen saturation is frequently observed in moderate to severe cases.
Crackles or rales may be heard on lung auscultation indicating pulmonary involvement.
Tachycardia can occur secondary to fever or hypoxia.
Conjunctival injection or mild pharyngeal erythema may be present in some cases.
Diagnostic Workup
Diagnostic Criteria
Use a viral NAAT (including RT-PCR) or antigen test, interpreted with symptoms, timing and exposure. Samples depend on the validated assay and may include nasal swabs or saliva. NAAT can remain positive after recovery, sometimes up to 90 days, so a positive result does not by itself prove ongoing infectiousness. A negative antigen test does not exclude early infection: follow serial testing instructions or obtain NAAT when indicated. Imaging supports assessment of pneumonia/complications but does not specifically identify SARS-CoV-2. Antibody testing is not the routine test for current infection.
Pathophysiology
Key Mechanisms
Spike binds ACE2; host proteases such as TMPRSS2 or endosomal proteases support entry, with pathway use varying by cell and variant.
Severe disease may involve impaired antiviral interferon responses and dysregulated inflammation. A uniform cytokine storm is not required in every patient.
Endothelial injury leading to microvascular thrombosis and coagulopathy.
Diffuse alveolar damage resulting in impaired gas exchange and acute respiratory distress syndrome (ARDS).
The positive-sense RNA genome supports translation of viral proteins; viral proteases process polyproteins and RNA-dependent RNA polymerase replicates RNA in the cytoplasm. These are antiviral targets.
| Involvement | Details |
|---|---|
| Organs | Lungs are the main organs affected, with viral pneumonia leading to hypoxemia and acute respiratory distress syndrome |
Heart may be involved via myocarditis, arrhythmias, or ischemic injury secondary to systemic inflammation | |
Acute kidney injury is multifactorial: hemodynamic disturbance, inflammation, hypoxia, microvascular injury and treatment-related factors can contribute. | |
Neurologic symptoms can arise from systemic illness, vascular injury or immune mechanisms; direct viral infection is not the universal explanation. | |
| Tissues | Upper-airway epithelium supports infection and transmission; severe lower-respiratory disease can injure alveolar tissue. |
Vascular endothelium is involved in microvascular injury and thrombosis contributing to multi-organ dysfunction | |
| Cells | Airway epithelial cells and type II pneumocytes are important targets; do not restrict infection to alveolar cells. |
Alveolar macrophages contribute to the inflammatory response and cytokine release in COVID-19 pneumonia | |
T lymphocytes mediate adaptive immune response but may undergo depletion in severe disease | |
Endothelial cells are involved in vascular inflammation and thrombosis associated with COVID-19 | |
| Chemical Mediators | IL-6 participates in severe inflammatory signaling and is a therapeutic target in selected hypoxemic patients; it is not the sole driver of all disease. |
Tumor necrosis factor-alpha (TNF-α) promotes inflammation and tissue damage in infected lungs | |
C-reactive protein (CRP) is an acute phase reactant elevated in systemic inflammation and used as a disease severity marker | |
D-dimer is a marker of cross-linked fibrin breakdown, not a mediator or a specific test for COVID-associated thrombosis. |
Treatments
Pharmacological Treatments
Remdesivir
- Mechanism:
A nucleotide prodrug whose active metabolite inhibits viral RNA-dependent RNA polymerase, disrupting SARS-CoV-2 RNA synthesis.
- Side effects:
Elevated liver enzymes
Nausea
Hypersensitivity reactions
- Clinical role:
Three-day IV treatment started within 7 days for eligible high-risk outpatients when selected; also used in appropriate hospitalized patients. Selection depends on disease stage and current guidance.
Dexamethasone
- Mechanism:
Glucocorticoid-receptor activation alters transcription of inflammatory genes and suppresses excessive host inflammation.
- Side effects:
Hyperglycemia
Immunosuppression
Psychiatric disturbances
- Clinical role:
For severe/critical COVID-19 requiring supplemental oxygen or ventilatory support; not routine therapy for uncomplicated nonhypoxemic infection.
Tocilizumab
- Mechanism:
Monoclonal antibody against soluble and membrane IL-6 receptors, reducing IL-6-mediated inflammatory signaling.
- Side effects:
Increased infection risk
Hepatotoxicity
Neutropenia
- Clinical role:
Additional immunomodulation with systemic corticosteroids in selected hospitalized patients with rapidly progressing severe or critical disease.
Baricitinib
- Mechanism:
JAK1/JAK2 inhibition reduces downstream cytokine signaling.
- Side effects:
Thrombosis
Infections
Elevated liver enzymes
- Clinical role:
An alternative additional immunomodulator to tocilizumab in selected severe/critical hospitalized adults receiving corticosteroids; adjust for renal function.
Nirmatrelvir/ritonavir (Paxlovid)
- Mechanism:
Nirmatrelvir inhibits SARS-CoV-2 main protease (Mpro/3CLpro); ritonavir inhibits CYP3A to increase nirmatrelvir exposure.
- Side effects:
Dysgeusia
Diarrhea
Potentially serious CYP3A-mediated drug interactions; hypersensitivity can occur
- Clinical role:
Preferred oral option for eligible high-risk mild/moderate disease, started within 5 days. Review all drug interactions and renal dosing; current labeling includes a severe-renal-impairment regimen. Not recommended in severe hepatic impairment.
Non-pharmacological Treatments
Supplemental oxygen therapy to maintain adequate oxygen saturation in hypoxemic patients
Use lung-protective mechanical ventilation for appropriate respiratory failure, with escalation based on physiology and goals of care.
Prone positioning can improve oxygenation and outcomes in appropriately selected ventilated ARDS; awake proning is a selected adjunct and must not delay needed intubation.
High-flow nasal oxygen may support selected hypoxemic patients with close monitoring; failure or inability to protect the airway requires reassessment and escalation.
Strict infection control measures including isolation and use of personal protective equipment
Prevention
Pharmacological Prevention
Updated mRNA vaccines reduce severe COVID-19 risk; they do not prevent every infection or all transmission.
A protein-subunit vaccine is another current US option. The Johnson & Johnson/Janssen vaccine is no longer authorized in the United States.
Pemivibart pre-exposure prophylaxis may be available for eligible moderately/severely immunocompromised people unlikely to respond adequately to vaccination. It is not a substitute for vaccination, treatment or post-exposure prophylaxis; check current authorization and variant susceptibility.
Antiviral agents are not currently recommended for primary prophylaxis but are used in treatment.
Use the current season’s age- and immune-status-specific vaccination guidance and product eligibility. Updated doses can restore protection as immunity wanes and variants change.
Non-pharmacological Prevention
Well-fitting masks or respirators reduce exposure to and emission of infectious respiratory particles; filtration and fit matter.
Physical distancing limits close contact and viral spread.
Hand hygiene remains useful, but it does not replace ventilation and respiratory protection against predominantly airborne spread.
Ventilation improvements in indoor spaces reduce airborne viral concentration.
In community settings, stay home while ill until symptoms improve overall and fever has been absent without fever reducers for at least 24 hours, then take added precautions for 5 days. Healthcare and immunocompromised situations may need different measures; follow current guidance.
Outcome & Complications
Complications
Acute respiratory distress syndrome (ARDS) is a life-threatening pulmonary complication.
Venous or arterial thrombosis can occur, particularly with severe illness; it is not an expected event in every infection.
Secondary bacterial pneumonia can complicate severe COVID-19 cases.
Myocarditis and cardiac arrhythmias may occur due to direct viral or inflammatory injury.
MIS-C, and less commonly MIS-A, is a delayed inflammatory complication after infection rather than a feature of every acute case.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
COVID-19 (SARS-CoV-2 - Coronaviruses) versus Influenza
COVID-19 (SARS-CoV-2 - Coronaviruses) | Influenza |
|---|---|
Community circulation with waves that are not confined to one season | Seasonal epidemics, often winter in temperate climates; timing alone does not distinguish infection |
SARS-CoV-2 NAAT or appropriately interpreted antigen testing | Influenza molecular testing or antigen testing; a negative rapid antigen result may miss infection, and coinfection can occur |
Severity and duration vary, with possible persistent post-acute symptoms | Often abrupt fever/myalgia/cough, but severity and duration vary; complications and prolonged symptoms can occur |
COVID-19 (SARS-CoV-2 - Coronaviruses) versus Respiratory Syncytial Virus (RSV) Infection
COVID-19 (SARS-CoV-2 - Coronaviruses) | Respiratory Syncytial Virus (RSV) Infection |
|---|---|
All ages; severe risk rises with age, immune compromise and other factors | All ages; severe disease particularly in infants, older adults and vulnerable patients |
Enveloped positive-sense single-stranded RNA virus, family Coronaviridae | Enveloped negative-sense nonsegmented RNA virus, family Pneumoviridae |
Often upper-respiratory illness; may cause pneumonia or systemic complications | Often cold-like illness; bronchiolitis in infants and lower-respiratory disease in vulnerable adults |
COVID-19 (SARS-CoV-2 - Coronaviruses) versus Bacterial Pneumonia
COVID-19 (SARS-CoV-2 - Coronaviruses) | Bacterial Pneumonia |
|---|---|
Inflammatory markers and leukocyte patterns are variable; PCT can be elevated in severe illness | Neutrophilia or elevated PCT may support suspicion, but their absence does not exclude bacterial pneumonia/coinfection |
Ground-glass or patchy opacities may occur but are nonspecific | Lobar or multifocal consolidation can occur; imaging patterns overlap with viral pneumonia |
Supportive care; early antivirals for eligible higher-risk patients. Antibiotics treat suspected bacterial coinfection, not SARS-CoV-2 itself | Antibiotics selected for likely pathogen and severity; response varies and is not an immediate confirmatory test |
COVID-19 (SARS-CoV-2 - Coronaviruses) versus Other Coronavirus Infections (e.g., SARS, MERS)
COVID-19 (SARS-CoV-2 - Coronaviruses) | Other Coronavirus Infections (e.g., SARS, MERS) |
|---|---|
Ongoing broad human-to-human circulation | MERS risk includes relevant travel, camel or healthcare exposure; SARS-CoV has had no reported cases since 2004 |
Positive PCR specific for SARS-CoV-2 | Positive PCR specific for SARS-CoV or MERS-CoV |
Spectrum from asymptomatic to critical disease; risk depends on host/variant/immunity | SARS and MERS have caused severe outbreaks with high reported case fatality, but ascertainment differs and severity alone cannot identify the virus |
COVID-19 (SARS-CoV-2 - Coronaviruses) versus Community-Acquired Pneumonia due to Atypical Bacteria (e.g., Mycoplasma pneumoniae)
COVID-19 (SARS-CoV-2 - Coronaviruses) | Community-Acquired Pneumonia due to Atypical Bacteria (e.g., Mycoplasma pneumoniae) |
|---|---|
No specific leukocyte or cold-agglutinin pattern establishes COVID-19 | Cold agglutinins may occur with M. pneumoniae but are neither sensitive nor specific; use appropriate respiratory testing |
Respiratory and systemic symptoms vary by patient and variant | Often gradual cough, but clinical presentation overlaps substantially with viral and other bacterial infections |
Antivirals are risk-selected, not required for every mild infection | Use appropriate pathogen-directed antibiotics; M. pneumoniae lacks a cell wall, so beta-lactams are ineffective |